Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.

Abstract

The role of beta2-microglobulin (β2-MG) in predicting acute kidney injury (AKI) in hemophagocytic lymphohistiocytosis patients has been poorly studied. This study aimed to analyze the clinical characteristics of hemophagocytic lymphohistiocytosis patients and identify risk factors that predict AKI development. This retrospective observational cohort study conducted ata single-centerinvolved 938 patients diagnosedwith hemophagocytic lymphohistiocytosis, who were divided into AKI groupand non-AKI group. Patient data were collected and analyzed usingunivariate and multivariate binary logistic regression to identify potiential risk factors associated with AKI occurrence. RESULTS: Among the enrolled patients, 486 were male (51.9%), the median age was 37years (interquartile range, 28.0, 52.0), 58.4%experienced AKI. Mechanical ventilation (8.0% vs. 0.8%) and vasopressor support (21.7% vs. 4.1%) occurred at significantly higher rates in the AKI group compared to the non-AKI group, with significantly higher in-hospital mortality (5.5% vs. 1.3%) and 28-day mortality (12.8% vs. 5.4%). When β2-MG was used as a continuous variable, multifactorial analysis showed that β2-MG, transplantation, and vasopressor support were independently associated with risk for the development of AKI. The incidence ofmorbidity and mortality in patients with hemophagocytic lymphohistiocytosis complicated by AKIremains high. Monitoring levels ofβ2-MG may provide clinicians with timely indicatorsofchanges in renal function, facilitating adjustments to treatment strategies.